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Malaria, which is caused by infection with the hemoproto­
zoan parasite Plasmodium, afflicts approximately 500 million 
people each year, leading to 2.7 million deaths annually world­
wide [1]. Malaria infections result in diverse clinical outcomes, 
presumably because of the dynamic relationship between par­
asite­expressed virulence factors and individual host responses 
to these determinants [2]. The last few years have seen a rapid 
growth in the number of reported genetic associations with 
host susceptibility and resistance to malaria; these are mainly 
variants in erythrocytes, cytoadherence factors, immune sys­
tem, and inflammatory genes [3­5]. However, the molecular 
basis of malaria infection remains incompletely defined. The 
identification of genetic factors involved in malaria susceptibil­
ity and resistance in both the host and the parasite would lead 
not only to a greater understanding of this complex disease 
but also potentially to development of effective medical inter­
ventions [2,6].
Interactions between Plasmodium and its host hepatocytic 
factors are of great research interest [7­9]. On one hand, it is 
well established that malaria sporozoites exploit signaling via 
the hepatocyte growth factor (HGF) and its receptor MET dur­
ing host invasion [10]. On the other hand, malaria is a life cy­
cle­specific disease that includes liver injury at the erythrocytic 
stage of the parasite [11]. Indeed, both humans and mice suf­
fer from liver injury after infection with the fatal strains of Plas­
modium falciparum (Pf) and Plasmodium berghei (Pb) [12,13]. 
Hepatic nuclear factor (HNF)­1α, a liver­specific transcription 
factor also designated as LF­B1 or TCF­1, is a critical compo­
nent of the regulatory network, affecting diverse metabolic 
functions in the liver, pancreatic islets, intestine, and kidneys. 
The gene encoding HNF­1α maps to chromosome 12q34 and 
functions as a dimer [14]. HNF­1α plays an important role in 
transactivation of hepatic genes during adaptive responses to 
liver injury [15,16]. Additionally, mutation in the gene is asso­
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Abstract: The onset, severity, and ultimate outcome of malaria infection are influenced by parasite-expressed virulence 
factors as well as by individual host responses to these determinants. In both humans and mice, liver injury follows para-
site entry, persisting to the erythrocytic stage in the case of infection with the fatal strain of Plasmodium falciparum. He-
patic nuclear factor (HNF)-1α is a master regulator of not only the liver damage and adaptive responses but also diverse 
metabolic functions. In this study, we analyzed the expression of host HNF-1α in relation to malaria infection and evaluat-
ed its interaction with the 5´-untranslated region of subtilisin-like protease 2 (subtilase, Sub2). Recombinant human HNF-
1α expressed by a lentiviral vector (LV HNF-1α) was introduced into mice. Interestingly, differences in the activity of the 
5´-untranslated region of the Pf-Sub2 promoter were detected in 293T cells, and LV HNF-1α was observed to influence 
promoter activity, suggesting that host HNF-1α interacts with the Sub2 gene.
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ciated with maturity­onset diabetes of the young type III (MO­
DY3) [16,17], indicating the important biological role of HNF­
1α in glucose metabolism. In addition, HNF­1α interacts with 
other transactivators to regulate the chromatin structure of the 
gene encoding the serine protease inhibitor, serpin [18]. P. fal­
ciparum subtilisin­like protease 2 (subtilase, Sub2) is an essen­
tial integral membrane serine protease in both Pf and Pb. It 
functions in shedding of the ectodomain components of 2 sur­
face proteins, membrane surface protein 1 (MSP1) and apical 
membrane antigen 1 (AMA1), upon host invasion [19,20]. 
The importance of the Sub2 gene is evidenced by the fact that 
Sub2 knock­out parasites cannot be recovered [21].
In this study, to understand HNF­1α interactions with the 
malaria antigen Sub2, the activity of the Pf­Sub2 promoter was 
estimated. We cloned the 5´­untranslated region (UTR) of Pf­
Sub2 from Pf genomic DNA (gDNA) and analyzed its tran­
scriptional activity when exogenous HNF­1α was over­expressed 
in 293T cells. 
Pf 3D7 strain was obtained from Malaria Research and Ref­
erence Reagent Resource Center (MR4; Manassas, Virginia, USA; 
http://www.mr4.org). Pf 3D7 culture conditions were set ac­
cording to the MR4 standard protocol. Parasitemia was calcu­
lated by counting at least 1,000 cells following staining with 
Diff Quik (Sysmex, Kobe, Japan). The parasitemia of about 
10% to 30% was continuously maintained.
Cell culture media and components, including fetal bovine 
serum (FBS) were obtained from Invitrogen (Carlsbad, Cali­
fornia, USA). All cells were purchased from the American Type 
Culture Collection (ATCC, Rockville, Maryland, USA) and were 
routinely cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS. HeLa and 293T cells 
were used for the experiments.
All plasmids were purified using JETstar2.0 mini and maxi­
prep Kit (GenoMed, St. Louis, Missouri, USA) according to the 
manufacturer’s instructions. Pf 3D7 small­scale gDNA isola­
tion followed the MR4 protocol. The HNF­1α cDNA clone was 
obtained from Open Biosystems (Accession No: BC104908; 
Rockford, Illinois, USA) and was amplified by PCR with prim­
ers F (5´­ATAGAA TTCGCAGCCGAGCCATGGTTTCTA­3´; EcoRI 
site underlined) and R (5´­ATACTCGAGTGCCGTGGTTACT­
GGGAGGAAG­3´; XhoI site underlined). The amplified frag­
ment was inserted into pCDNA3­Flag­HA (Addgene, Cambri­
dge, Massachusetts, USA) by EcoRI and XhoI ligation. Lentivi­
rus (LV) HNF­1α was constructed by cutting the LV plasmid 
backbone with BamHI and XbaI to expel the resident luciferase 
gene, which was replaced with a HNF­1α cDNA insert cut from 
pCDNA3­HNF­1α­Flag­HA. A construct for luciferase activity 
was based on a pGL3­Basic vector (Promega, Madison, Wis­
consin, USA). Two different 5´­upstream sequences flanking 
the Pf­Sub2 gene were amplified from Pf 3D7 gDNA with pri­
mers. The primers used for ­2,567/+32 UTR were F (5´­ATAG­
GTACCTAGAATAGAATAAAATAAATAACC­3´; KpnI site under­
lined) and R (5´­ATAAAGCTTATCAAGGAAACCACATAA­3´; 
HindIII site underlined). The primers used for ­1,422/+12 UTR 
were F (5´­AAGGTACCATGGTATGAGTTCTTTATA­3´; KpnI site 
underlined) and R (5´­ATGCTAGCAATATTCAGCATTATACG­
GA­3´; NheI site underlined). PCR was performed using a TGR­
ADIENT thermocycler (Biometra, Goettingen, Germany). The 
amplified UTR sequences were cloned into a pMDT vector (Ta­
kara Bio, Shiga, Japan) and subcloned into a pGL3­Basic vec­
tor with KpnI and NheI/HindIII sticky end ligation, generating 
the pGL3­Basic­Pf­Sub2 5´­UTR construct. The other upstream 
inserts were cloned into a pGL3­Basic vector by blunt restric­
tion sites (EcoRV, SnaBI and SwaI) located in the 1.5­kb region 
upstream of the luciferase gene. The internal control was pSV­
β­galactosidase (Promega). All clones were analyzed by restric­
tion mapping and were sequenced by a 3730XL DNA sequenc­
er (Macrogen, Seoul, Korea).
A human immunodeficiency virus (HIV)­1­based LV plas­
mid system, including the LV backbone with luciferase gene 
flanked at the 5´­end by cytomegalovirus vector (CMV) pro­
moter, pCMV dR8.91 packaging construct, and pMDG2 enve­
lope plasmid, were kindly provided by Dr. Didier Trono. The 
pseudo­typed LV was generated by co­transfecting these plas­
mids into 293T cells using the calcium phosphate method [22]. 
LV was concentrated by overlaying the viral supernatant on a 
20% sucrose cushion and centrifuging at 12,000 rpm for 2 hr 
at 4˚C in a Beckman SW28 swing bucket rotor. Aliquots of the 
concentrated virus were stored at ­80˚C. LV preparation quality 
was determined by using serial dilutions of the concentrated 
frozen viral stock to infect HeLa cells contained in 6­well plates 
(NUNC, Roskilde, Denmark). After 48 hr incubation, lucifer­
ase activity of cells infected with 10 µL of a concentrated virus 
suspension was determined. The recombinant HNF­1α was 
analyzed with an anti­HNF­1α antibody by western blotting as 
described below.
Five­week­old mice were injected with LV HNF­1α through 
the tail vein. The 200 µl injected volume varied in potency 
from a low dose consisting of 20 µl concentrated LV HNF­1α 
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consisting of 200 µl of concentrated LV HNF­1α. Blank control 
mice were injected with the same volume of PBS, and mimic 
control mice were injected with the LV backbone lacking HNF­
1α. DNA isolated from liver tissue from LV HNF­1α­infected 
mice was subjected to reverse transcription (RT)­PCR with hu­
man HNF­1α­specific primers that contained the maximum 
number of critical mismatches with the homologous mouse 
sequence (F: 5´­CCCTGGCCTGCCTCCACCTG­3´ and R: 5´­GG­
GTCACATGGCTCTGCACAGGT­3´).
Cells were harvested and lysed with RIPA buffer (Pierce, Rock­
ford, Illinois, USA) with freshly added protease inhibitor cock­
tail (Sigma­Aldrich, St. Louis, Missouri, USA). One hundred 
micrograms of cell lysate was diluted with a loading buffer that 
contained a reducing agent, and proteins were separated on 
12% SDS­PAGE and transferred to a polyvinylidene fluoride 
membrane. Immunoblotting was performed with a 1:200 di­
lution of rabbit polyclonal anti­HNF­1α antibody (SC10791; 
Santa Cruz Biotechnology, Santa Cruz, California, USA) in 3% 
bovine serum albumin (BSA). The secondary antibody, poly­
clonal goat anti­rabbit IgG conjugated with horseradish perox­
idase (HRP) (Dako, Glostrup, Denmark), was used at a 1:1,000 
dilution in PBS. For proliferating cell nuclear antigen (PCNA) 
quantification, anti­PCNA/HRP monoclonal antibody was used 
(Dako).
Cells were transfected with 2.5 µg of the reporter constructs 
and 0.5 µg of pCMV­β­galactosidase by a standard calcium 
phosphate co­precipitation method in 6­well plates. For co­
transfection, 1.5 µg of the reporter constructs and 0.5 µg of 
pCMV­β­galactosidase were co­transfected with different amo   
unts of pCDNA­HNF­1α­Flag­HA (0.5­4.5 µg). Each sample 
was analyzed in duplicate and each experiment was repeated 
twice. Luciferase and β­galactosidase activities were measured 
using a model LB96V microplate luminometer (Berthold Tech­
nologies, Bad Wildbad, Germany) according to the manufac­
turer’s instructions. Luciferase activity was normalized with re­
spect to β­galactosidase activity to correct deviation due to trans­
fection efficiencies and cell numbers.
HNF­1α gene expression was observed both in vitro and in 
vivo. To determine LV HNF­1α production, 20 µl and 200 µl 
of non­concentrated (approximately 1×10
7 transducing units 
(TU)/mL) or 20 µl of concentrated (approximately 10
9 TU/
mL) LV HNF­1α was used to infect cultured HeLa cells. After 
48 hr, western blot analyses using monoclonal anti­HNF­1α 
antibody revealed strong gene expression in cells infected with 
20 µl of concentrated LV HNF­1α (Fig. 1A). Six days following 
injection of LV backbone and LV HNF­1α into mice, luciferase 
gene expression was detected in peripheral blood (data not 
shown). To confirm the expression of human HNF­1α gene in 
mice, RT­PCR was performed with mice liver tissues. Human 
HNF­1α was amplified in mice infected with LV HNF­1α but 
not in mice injected with the mimic LV backbone or PBS (Fig. 
1B). 
To analyze the influence of HNF­1α on the transcriptional 
activity of 5´­UTR of Pf­Sub2 in vitro, co­transfection of pGL3­
Basic­Pf­Sub2 5´­UTR with different amounts of HNF­1α was 
performed in 293T cells. The exogenous HNF­1α expression 
level of pCDNA­HNF­1α­Flag­HA in transfected 293T cells was 
ascertained by western blotting with anti­HNF­1α antibody 
(Fig. 2A). High HNF­1α expression was observed using 4.5 μg 
of the pCDNA­HNF­1α­Flag­HA transfection vector. Except for 
the ­329/+12 UTR, the 5´­UTRs showed high and distinct tran­
scriptional luciferase activities (Fig. 2B). As the amount of pCD­
NA­HNF­1α­Flag­HA vector increased from 0.5 to 4.5 μg, lucif­
erase activity was increased. Although the ­1,422/+12 UTR did 
not drive the luciferase activity in a similar manner as apparent 
Non-concentrated LV HNF-1α
Anti-HNF-1α
Anti-PCNA
Concentrated LV HNF-1α
200 μl 20 μl 20 μl 20 μl Producer Bank
A
Control
M - +
200 μl PBS-injected
200 μl LV backbone-injected
20 μl LV HNF-1α plus 180 μl PBS-injected
200 μl LV HNF-1α-injected
B
Fig. 1. Expression of LV HNF-1α. (A) Western blot using an anti-
HNF-1α antibody in HeLa cells transduced with concentrated or 
non-concentrated LV HNF-1α and using an anti-PCNA antibody 
as a loading control. (B) HNF-1α mRNA expression in transduc-
ed mice liver tissues as assessed by RT-PCR.434   Korean J Parasitol Vol. 49, No. 4: 431-436, December 2011
in Fig. 2A, a significant difference was seen with 1.5 μg of pGL3­ 
Basic­Pf­Sub2 5´­UTR/4.5 μg of pCDNA­HNF­1α­flag­HA as 
compared with only 1.5 μg of pGL3­Basic­Pf­Sub2 5´­UTR. 
HNF­1α is a critical regulator of diverse metabolic functions 
in the liver, pancreatic islets, intestine, and kidneys. It is essen­
tial for glucose, bile acid, and plasma cholesterol metabolism 
[15,16,23]. However, further details pertaining to HNF­1α func­
tion remain to be resolved. HNF­1α not only physically inter­
acts with basic transcriptional machinery, such as histone acet­
yltransferases (HATs), CREB­binding protein (CBP), and p300/ 
CBP­associated factor (P/CAF) [24], but also plays an impor­
tant role in modulation of chromatin structure, as in the case 
of hyperacetylation of the serpin gene [18,25]. Hence, exoge­
nous HNF­1α signaling cascades might influence basic regula­
tory networks, metabolic states, and immune system function­
ing of the host, thereby indirectly influencing the infecting Plas­
modium. Since the molecular and cellular factors mediating 
differences in malaria virulence and severity are poorly under­
stood [26], the present study might lay the groundwork for re­
search investigating different natural outcomes of malaria in­
fections.
The mechanism of HNF­1α regulation in mammals is not 
fully understood. Moreover, clarifying transcription regulation 
in the Plasmodium genome is onerous because of the genome’s 
abnormal AT­richness [27,28]. Nonetheless, Plasmodium genes 
are organized similarly to those in eukaryotes and are also mo­
nocistronically transcribed [29­31], implying the presence of 
regulatory sequence elements flanking the coding regions [32, 
33]. For example, the region upstream to the Pf multidrug re­
sistance gene can be induced at the transcriptional level by an­
timalarial drugs in chloroquine­sensitive parasites [34]. Our 
results obtained from upstream transcriptional activities of Pf­
Sub2 demonstrate that the proximal promoter of Pf­Sub2 is 
influenced by exogenous HNF­1α. Although the effect of HNF­
1α on malaria gene expression in cultured cells may be indi­
rect or atypical, the present results indicate the feasibility of 
regulation of genes important for malaria invasion via host­
parasite interaction. 
The present study has shown that exogenous human HNF­
1α expression is involved in host response to malaria infec­
tion. Interestingly, host HNF­1α interacts at the mRNA level 
with the parasite serine protease Sub2, which is important in 
host cell invasion by the malarial parasite. Specific upstream 
regions are important in the activity of the protease. Taken to­
gether, these data suggest that human HNF­1α interacts with 
the promoter regions of the Sub2 gene. Future studies will be 
aimed at elucidating the role of HNF­1α in malaria sensitivity/
resistance and how Sub2 gene expression is influenced by the 
host HNF­1α signaling cascade. 
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